Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Frequently asked questions
What sector does Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) operate in?
Recursion Pharmaceuticals, Inc. Class A Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) current stock price?
As of the latest data, Recursion Pharmaceuticals, Inc. Class A Common Stock stock price is $3.80, with a previous close of $3.70. Recursion Pharmaceuticals, Inc. Class A Common Stock gained $0.10 in the last trading session, representing a 2.7% increase.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) current market capitalization?
Recursion Pharmaceuticals, Inc. Class A Common Stock market cap is approximately 2.03 billion.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Earnings Per Share (EPS)?
The trailing EPS is -$1.09, and the forward EPS is -$0.90.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) EBITDA?
Recursion Pharmaceuticals, Inc. Class A Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -112.53 million.
Does Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) pay dividends?
No. Recursion Pharmaceuticals, Inc. Class A Common Stock does not pay a dividend.
How did Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) perform in its most recent earnings report?
In the last report (June 30, 2026), Recursion Pharmaceuticals, Inc. Class A Common Stock posted an EPS surprise of -8.7% and a revenue surprise of -35.89%.
When is Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) next earnings report?
Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to release its next earnings report on September 30, 2026.
What is Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) beta (volatility) score?
Recursion Pharmaceuticals, Inc. Class A Common Stock has a beta of 1.032, meaning its volatility is roughly in line with the market.
